Table 1. Efficacy Results of Studies in FLa.
| Trial | Regimen | Study population | ORR, % | mPFS | mOS |
|---|---|---|---|---|---|
| Immunomodulatory therapy | |||||
| McLaughlin, Piro, and Davis trials | Rituximab | R/R low-grade or follicular NHL (N = 296) | 36–57 | — | — |
| AUGMENT | Lenalidomide + rituximab | R/R FL, ≥ 1 prior systemic therapy, not rituximab-refractory (n = 295) | 80 | 39.4 months | 95% at 2 yearsb |
| Rituximab | 55 | 13.9 months | 86% at 2 yearsb | ||
| CAR T-cell therapy | |||||
| ZUMA-5 | Axicabtagene ciloleucel | 3L R/R FL (n = 123) | 94 | 73% at 18 monthsc | 92% at 18 monthsb |
| ELARA | Tisagenlecleucel | 3L R/R FL (N = 97) | 86 | 67% at 12 monthsc | — |
| Bispecific antibody therapy | |||||
| GO29781 | Mosunetuzumab | 3L R/R FL (N = 90) | 80 | 17.9 months | 90% at 18 monthsb |
| EZH2 inhibitor | |||||
| E7438-G000-101 | Tazemetostat | 3L R/R FLd (N = 99) | 51 | 12 months | NR |
| PI3K inhibitor | |||||
| CHRONOS-1 | Copanlisib | 3L R/R FL (n = 104) | 59 | 11.2 months | — |
Note. 3L = third-line; CAR T-cell therapy = chimeric antigen receptor T-cell therapy; EZH2 = enhancer of zeste homolog 2; FL = follicular lymphoma; mOS = median overall survival; mPFS = median progression-free survival; NHL = non-Hodgkin lymphoma; NR = not reported; ORR = objective response rate; PI3K = phosphoinositide 3 kinase; R/R = relapsed/refractory.
a
Table 1 does not represent head-to-head trials. Head-to-head trials have not been conducted among the listed agents.
b
OS; estimated from survival curves when not available.
c
PFS; estimated from survival curves when not available.
d
Includes wildtype and mutant-type EZH2.